Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS

Trial Profile

A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Brainstorm Cell Therapeutics
  • Most Recent Events

    • 25 Nov 2019 According to an Brainstorm Cell Therapeutics media release, the company announced that The Mount Sinai Medical Center has contracted with the company as a clinical study site for this study and Dr. Fred Lublin will serve as the principal investigator at this site.
    • 14 Nov 2019 According to an Brainstorm Cell Therapeutics media release, the company continues to enroll patients in several of the leading U.S. medical centers and anticipates announcing additional investigational centers of excellence in the near future. The first eight (8) participants have been enrolled in the study.
    • 14 Nov 2019 According to a Brainstorm Cell Therapeutics media release, the Company has received grant from the National Multiple Sclerosis Society for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top